New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 9, 2014
07:08 EDTIMMUImmunomedics announces presentation of epratuzumab data
Immunomedics announced that scientific data on epratuzumab, an investigational therapy for the treatment of systemic lupus erythematosus, also known as lupus, will be presented at the European League Against Rheumatism 2014 Annual Congress to be held in Paris, France. Epratuzumab is an investigational medicine in Phase III clinical development for the treatment of SLE. Epratuzumab is a monoclonal antibody that targets CD22. Epratuzumab is not approved for the treatment of SLE by any regulatory authority worldwide. Immunomedics has granted UCB exclusive worldwide rights to develop, market, and sell epratuzumab for all autoimmune disease indications.
News For IMMU From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
June 26, 2015
15:31 EDTIMMUImmunomedics volatility elevated
Immunomedics July call option implied volatility is at 199, August is at 176, November is a 145; compared to its 52-week range of 53 to 198, suggesting large price movement.
June 17, 2015
14:32 EDTIMMUImmunomedics options active
Immunomedics July 7 and August 4 calls are active on total call volume of 8K contracts (3K puts). June call option implied volatility is at 176, July is at 226, August is at 163; compared to its 52--week range of 53 to 173. Active call volume suggests traders taking positions for price movement.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use